Anti-Obesity Drug Targets the CB1 Receptor via the Endocannabinoid System with Punit Dhillon Skye Bioscience

Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain. Deploying the endocannabinoid system, their lead drug candidate targets the major organs where CB1 receptors reside in fat tissue to increase mitochondrial activity and burn more fat.  Punit explains, "Skye is focused on exploring research modulating different therapeutic targets via the endocannabinoid system. Our research has narrowed in on the CB1 receptor, where we're modulating it by focusing on this pathway of inhibition. There's a big body of evidence, actually existing validation of this cannabinoid receptor 1 being a really important target to reduce caloric food intake and increase energy expenditure. It's been a really important target for weight loss because of its particular relevance in that therapeutic area. So we're advancing in a very interesting clinical pipeline and immediately a Phase 2 study that will look at that particular target. We hope that we will be able to show its relevance in the anti-obesity medication landscape." "I feel like the current landscape of drugs that have been getting the most attention has been focused on caloric restriction. Weight loss is driven by that particular pathway of restricting the amount you eat. We are trying to shift that paradigm to the opportunity to address the underlying issues relating to weight loss so you can essentially have this aspect of targeting fat and being able to address fat metabolism. That comes back to this link to the exercise comment you made because it's driving the underlying mitochondrial activity, which is helping to improve the thermogenesis and the conversion of that fat into thermogenic energy."  #SkyeBioscience #Obesity #EndocannabinoidSystem #WeightLossDrug #CB1Receptor #GLP1 skyebioscience.com Download the transcript here